💡Excited to share our latest work in @NatureComms! We identified promising host-directed therapies for TB meningitis using mouse models, human brain organoids, and patient immune cells. A step toward better treatments for this devastating disease
🔗 https://t.co/zXzBIJmxf6
March 24 marks World Tuberculosis Day, commemorating the discovery of the bacterium that causes TB in 1882. Today, we recognize the progress made, and the work still ahead, to end this preventable and treatable disease #WorldTBDay
📢 New preprint on host-directed therapy for TB meningitis.
Screening 12 immunomodulators across mouse models, human brain organoids, and patient PBMCs identifies candidates that reduce neuroinflammation and improve survival. 🧠🦠
https://t.co/S5FdYJXNHc
🙌🏻Excited to share our new paper in @JIDJournal: rifapentine- and rifabutin-based regimens achieved strong brain bactericidal activity and were associated with less neuroinflammation and neuronal injury vs rifampin
👉🏻 https://t.co/L4Vet99xSG
Shoutout to @XueyiChen and @MedhaSingh_18 for presenting their #TBResearch at the #IDWeek2025! One’s sharing insights via oral presentation, the other with a poster session🦠👏 Huge congrats to both on receiving the travel award!
A heartfelt thanks to the organizers and peers at #WMIC2025. Presenting our research on molecular imaging for infectious diseases was both an honor and a reminder of the importance of collaboration in advancing global health
Thrilled to be a co-author on our latest work in @NatureComms! We show how ¹⁸F-FDS PET can noninvasively detect and localize invasive mold infections—even when other methods fail.
🧠🫁 A step forward for immunocompromised patient care.
🔗 https://t.co/b9AxjHyQs3
🚨New paper out!
We demonstrate that 18F-FDS PET enables noninvasive, whole-body detection of invasive mold infections. A step forward in diagnosing life-threatening fungal disease
🔗 https://t.co/uMjDFw0DI4
🚨 New study out in @ATSBlueEditor: PET imaging can distinguish Mycobacteroides abscessus infection from sterile inflammation—offering a noninvasive diagnostic tool for vulnerable patients with underlying lung disease
🔗 https://t.co/ZF5GYyZ2Yz
Host-directed therapy breakthrough! Navitoclax, a Bcl-2 inhibitor, improves pulmonary TB treatment by promoting bacterial clearance, reducing tissue necrosis, and preventing fibrosis. A potential game changer for post-TB lung disease! Read more in: https://t.co/8XhaAAvVxa
🚨 New from @johngreen: Everything Is Tuberculosis 📖🩻 A powerful exploration of TB’s impact on global health, history, and humanity. A must-read for anyone invested in the fight to #EndTB! So grateful with @HopkinsTRAC for this copy #WorldTBDay
On #WorldTBDay, we highlight the fight against tuberculosis, a preventable and treatable disease that still claims millions of lives. Research, innovation, and access to care are key to #EndTB 🔬🌍
🚨Nuevo artículo: la meningitis tuberculosa es una de las principales causas de mortalidad extra pulmonar. Proponemos nuevos regímenes de tratamiento, con mejor penetración en el sistema nervioso, están detallados en: https://t.co/rikY3PII8A